Related Experiment Videos
Multidrug resistance in leukemia
1Cancer Research Facility, Albuquerque, NM 87131, USA.
Abstract:
Resistance of tumors to chemotherapeutic agents is an important factor that limits the successful treatment of a wide range of malignancies. The multidrug resistant (MDR) phenotype is well recognized in clinical samples, and it has been extensively studied, particularly in acute myeloid leukemia. One of the principle mechanisms underlying this MDR phenotype is the active cellular extrusion of chemotherapeutic agents by the multidrug resistance protein MDR1 (p-glycoprotein). More recently, other drug resistance proteins, notably the multidrug resistance-associated protein, MRP, and the lung resistance protein, LRP, have also been implicated in multidrug resistance. This review summarizes recent contributions in this field. In particular, it focuses on recent efforts to better measure MDR in clinical samples, a critical step in correctly determining the MDR phenotype of a patient's tumor.
Insights
Tumor resistance to chemotherapy, known as multidrug resistance (MDR), hinders cancer treatment. This review highlights new methods for measuring MDR in clinical samples to improve patient outcomes.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Tumor resistance to chemotherapy is a major obstacle in treating various cancers.
- The multidrug resistant (MDR) phenotype is frequently observed in clinical settings, especially in acute myeloid leukemia.
- Key mechanisms of MDR involve drug efflux pumps like MDR1 (p-glycoprotein), MRP, and LRP.
Purpose of the Study:
- To review recent advancements in understanding and measuring multidrug resistance in clinical samples.
- To emphasize the importance of accurate MDR assessment for effective cancer patient management.
Main Methods:
- Review of recent scientific literature focusing on multidrug resistance mechanisms and detection.
- Analysis of emerging techniques for quantifying MDR in patient tumor samples.
Main Results:
- Identification of multiple drug resistance proteins (MDR1, MRP, LRP) contributing to chemotherapy resistance.
- Progress in developing and validating methods for measuring MDR in clinical oncology.
Conclusions:
- Accurate measurement of MDR in patient tumors is crucial for tailoring chemotherapy regimens.
- Continued research into MDR mechanisms and detection methods is vital for improving cancer treatment efficacy.